Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma.

doi:10.1038/s41416-020-01244-2

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma.

British journal of cancer - 1 Mar 2021

Teo Min Yuen, Al-Ahmadie Hikmat, Seier Kenneth, Tully Christopher, Regazzi Ashley M, Pietzak Eugene, Solit David B, Tickoo Satish, Reuter Victor, Cha Eugene K, Herr Harry, Donahue Timothy, Donat Sherri M, Dalbagni Guido, Bochner Bernard H, Funt Samuel, Iyer Gopakumar V, Bajorin Dean F, Ostrovnaya Irina, Rosenberg Jonathan E

Abstract excerpt

BACKGROUND: Plasmacytoid urothelial carcinoma (PUC) is a rare, aggressive histologic variant of urothelial cancer characterised by a diffuse growth pattern and CDH1 mutation. We studied the efficacy of preoperative platinum-based chemotherapy in nonmetastatic PUC and immune checkpoint inhibitors (ICIs) in advanced PUC. METHODS: Cases of nonmetastatic PUC and advanced PUC treated with ICIs at our institution were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Follow-Up Studies

Share to Immune Checkpoint Inhibitors

Share to Neoadjuvant Therapy

Share to Prognosis

Share to Survival Rate

Share to Urinary Bladder Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 33473164
DOI: 10.1038/s41416-020-01244-2
PMCID: PMC8007750

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma.PMID 33473164Read ↗

Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma.Semantic proximity Read ↗

Metastatic Plasmacytoid Bladder Cancer Harboring a CDH-1 Mutation and Producing High Levels of CA 19-9. A Case Report and Literature Review.Semantic proximity Read ↗

The plasmacytoid carcinoma of the bladder--rare variant of aggressive urothelial carcinoma.Semantic proximity Read ↗

Plasmacytoid urothelial carcinoma of the urinary bladder-A clinicopathological and molecular analysis of 52 cases.Semantic proximity Read ↗

Advances in Therapy for Urothelial and Non-Urothelial Subtype Histologies of Advanced Bladder Cancer: From Etiology to Current DevelopmentSemantic proximity Read ↗

Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial Carcinoma.Semantic proximity Read ↗

A Molecular Taxonomy for Urothelial CarcinomaSemantic proximity Read ↗

Cytotoxic and DNA-targeted therapy in urothelial cancer: have we squeezed the lemon enough?Semantic proximity Read ↗

Prognostic Genetic Signatures in Upper Tract Urothelial Carcinoma.Semantic proximity Read ↗

A Case Series: High PD-L1 Expression and Postoperative Immunotherapy Response in Four Cases of Sarcomatoid Urothelial CarcinomaSemantic proximity Read ↗

Pure high-grade papillary urothelial bladder cancer: a luminal-like subgroup with potential for targeted therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.